Bill > SB212

This bill establishes the Prescription Drug Cost and Affordability Review Act, which creates two key bodies: the Prescription Drug Affordability Board and the Prescription Drug Affordability Stakeholder Council. The board, comprised of five governor-appointed members with expertise in healthcare economics, policy, and medicine, will have the power to review and potentially set upper payment limits for certain prescription drugs that meet specific cost criteria, such as brand-name drugs with annual costs over $60,000 or generic drugs with significant price increases. The 21-member stakeholder council, representing various stakeholders like manufacturers, healthcare providers, employers, and patient advocates, will assist the board in its decision-making. Beginning in January 2027, the board can select prescription drugs for review based on factors like wholesale acquisition cost, price increases, and potential affordability challenges. If the board determines a drug creates affordability issues, it can establish an upper payment limit that prescription drug purchasers and third-party payers must follow. The bill also requires annual reporting to the legislature about drug price trends and recommendations for improving prescription drug affordability. A prescription drug affordability fund will be established to support the board's operations, and the board is prohibited from using certain cost-effectiveness measures that could discriminate based on age, illness severity, or disability.

Business and Industry

https://kslegislature.gov/li/b2025_26/measures/sb212/